Skip to main content

Table 2 Demographic data and baseline characteristics (randomised set)

From: Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study

 

Total

Intradermal vaccine

Adjuvanted vaccine

 

N = 795

N = 398

N = 397

Mean age (years; SD)

74.3 (6.4)

73.9 (6.3)

74.7 (6.6)

   - over 75 (n; %)

329 (41.4)

154 (38.7)

175 (44.1)

Males (n; %)

370 (46.5)

194 (48.7)

176 (44.3)

Mean body mass index (kg/m2; SD)

27.1 (4.5)

27.0 (4.5)

27.2 (4.5)

Past or current significant medical history (n; %)

715 (89.9)

358 (89.9)

357 (89.9)

   - risk factor a (n; %)

419 (52.7)

216 (54.3)

203 (51.1)

   - history of allergy b (n; %)

67 (8.4)

29 (7.3)

38 (9.6)

Last influenza vaccination c

   

   - previous season 2006-2007 (n; %)

576 (72.5)

287 (72.1)

289 (72.8)

   - prior to previous season (n; %)

57 (7.2)

26 (6.5)

31 (7.8)

  1. Percentages are based on the number of randomised subjects having available data
  2. a At least one of the following: lung disease, heart disease, diabetes, renal disease, neurological abnormality or other significant medical history such as HIV, cancer, hepatitis (A, B, C), epilepsy, auto-immune diseases or blood disorders reported during the medical history review
  3. b At least one allergic condition reported as medical history
  4. c Percentages are calculated based on the number of randomised subjects who had previously been vaccinated against influenza and who had available data. 7 subjects (4 from the intradermal vaccine group and 3 from the adjuvanted vaccine group) had previously been vaccinated against influenza by the intradermal route
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us